Literature DB >> 36099095

Increasing Seizure Activity During Radiation Treatment for High-grade Gliomas - Final Results of a Prospective Interventional Study.

Dirk Rades1, Jaspar Witteler2, Peter Trillenberg3, Denise Olbrich4, Steven E Schild5, Søren Tvilsted6, Troels W Kjaer7.   

Abstract

BACKGROUND/AIM: Little is known regarding seizures during radiotherapy for brain tumors. This prospective study investigated seizure activity in patients irradiated for high-grade gliomas. PATIENTS AND METHODS: Using a seizure diary, progression of seizure activity was evaluated in 22 patients receiving chemoradiation for grade III (n=1) or IV (n=21) gliomas. Progression was defined as increased frequency of any and/or generalized seizures (>50%) or increased anti-epileptic medication (≥25%). Patients' satisfaction with the diary was assessed using a questionnaire (six scales of 1-7 points). Uni- and multivariable analyses were performed including baseline seizure activity, age, sex, resection, tumor site, performance score, and history of epilepsy/seizures.
RESULTS: Ten patients (45%) experienced progression of seizure activity during their radiotherapy course, mainly due to increased seizure frequency (nine patients=41%). Mean values of patients' satisfaction scores ranged between 3.92 and 4.92 points.
CONCLUSION: Radiotherapy of high-grade gliomas can increase seizure activity. Patients require close monitoring to initiate or adjust anti-epileptic medication.
Copyright © 2022, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Seizures; chemoradiation; high-grade gliomas; patient reported outcomes; radiotherapy

Mesh:

Year:  2022        PMID: 36099095      PMCID: PMC9463928          DOI: 10.21873/invivo.12961

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.406


  15 in total

1.  Epileptic features and survival in glioblastomas presenting with seizures.

Authors:  Manuel Toledo; Silvana Sarria-Estrada; Manuel Quintana; Xavier Maldonado; Francisco Martinez-Ricarte; Jordi Rodon; Cristina Auger; Miren Aizpurua; Javier Salas-Puig; Estevo Santamarina; Elena Martinez-Saez
Journal:  Epilepsy Res       Date:  2016-12-26       Impact factor: 3.045

2.  Seizures Prior to Radiotherapy of Gliomas: Prevalence, Risk Factors and Survival Prognosis.

Authors:  Jaspar Witteler; Troels W Kjaer; Soeren Tvilsted; Steven E Schild; Dirk Rades
Journal:  Anticancer Res       Date:  2020-07       Impact factor: 2.480

Review 3.  Seizures at presentation are correlated with better survival outcomes in adult diffuse glioma: A systematic review and meta-analysis.

Authors:  Xing Fan; Yucai Li; Xia Shan; Gan You; Zhifeng Wu; Zhibao Li; Hui Qiao; Tao Jiang
Journal:  Seizure       Date:  2018-04-25       Impact factor: 3.184

4.  Radiation-induced brain disorders in patients with pituitary tumours.

Authors:  A Bhansali; A K Banerjee; A Chanda; P Singh; S C Sharma; S N Mathuriya; R J Dash
Journal:  Australas Radiol       Date:  2004-09

Review 5.  Epilepsy and brain tumors.

Authors:  Dario J Englot; Edward F Chang; Charles J Vecht
Journal:  Handb Clin Neurol       Date:  2016

6.  Factors influencing seizures in adult patients with supratentorial astrocytic tumors.

Authors:  S-L Hwang; C-L Lin; K-S Lee; A-S Lieu; T-H Kuo; C-Z Chang; C-P Yen; C-K Lin; J-K Loh; T-Y Huang; S-L Howng
Journal:  Acta Neurochir (Wien)       Date:  2004-05-24       Impact factor: 2.216

7.  A prospective interventional study evaluating seizure activity during a radiotherapy course for high-grade gliomas (SURF-ROGG).

Authors:  Dirk Rades; Jaspar Witteler; Denise Olbrich; Peter Trillenberg; Steven E Schild; Soeren Tvilsted; Troels W Kjaer
Journal:  BMC Cancer       Date:  2021-04-09       Impact factor: 4.430

Review 8.  Epidemiology of Brain and Other CNS Tumors.

Authors:  Quinn T Ostrom; Stephen S Francis; Jill S Barnholtz-Sloan
Journal:  Curr Neurol Neurosci Rep       Date:  2021-11-24       Impact factor: 6.030

9.  Prevalence of symptoms in glioma patients throughout the disease trajectory: a systematic review.

Authors:  Margriet IJzerman-Korevaar; Tom J Snijders; Alexander de Graeff; Saskia C C M Teunissen; Filip Y F de Vos
Journal:  J Neurooncol       Date:  2018-10-30       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.